Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.
Hope S. Rugo(City of Hope), Kathleen I. Pritchard, Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Hugues Bourgeois(Barwon Health), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Tarek Sahmoud(European Organisation for Research and Treatment of Cancer), Pabak Mukhopadhyay, Shaker R. Dakhil(Cancer Center of Kansas), Tibor Csőszi, Mario Campone(Institut de Cancérologie de l'Ouest), Vichien Srimuninnimit(Siriraj Hospital), Howard A. Burris(Deaconess Hospital), Tanya Taran, Puttisak Puttawibul(Prince of Songkla University), Martine Piccart(Université Libre de Bruxelles), Karen A. Osborne(Novartis (Switzerland)), Shinzaburo Noguchi(Hyogo Prefectural Nishinomiya Hospital), José Baselga(Novartis (Switzerland)), Daniel Yick Chin Heng(University of Calgary), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group)
Cited by 4
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k